Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 9:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 1,069 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo, Cohort 3 Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7594 Inhaled Formulation in Healthy Japanese Men

NCT02645253
View directory record Official record
Conditions
Asthma, Chronic Obstructive Pulmonary Disease COPD
Interventions
AZD7594 inhalation powder (200 μg), AZD7594 inhalation powder (400 μg), AZD7594 pressurized inhalation suspension (200 μg), AZD7594 placebo inhalation powder, AZD7594 placebo pressurized inhalation suspension
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
20 Years to 45 Years · Male only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Oct 13, 2026, 9:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetic Study of Anthrax Immune Globulin Derived From Human Serum

NCT00448253
View directory record Official record
Conditions
Symptoms of Inhalational Anthrax
Interventions
NP-015
Biological
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 55 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 13, 2026, 9:05 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Evaluation of D3 Receptor Occupancy Using FLUORTRIOPRIDE ([18F]FTP) PET/CT

NCT02815917
View directory record Official record
Conditions
D3 Dopamine Receptor, Cocaine-dependent, Healthy Volunteer
Interventions
[18F]FTP PET/CT
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 13, 2026, 9:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Different Amounts of the Study Medicine Called PF-07328948 Are Tolerated and Act in the Body in Healthy Adults

NCT05807490
View directory record Official record
Conditions
Healthy
Interventions
PF-07328948, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 19, 2024 · Synced Oct 13, 2026, 9:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First-in-Human Study to Evaluate Safety and Tolerability of Single and Multiple Ascending Doses of Janus Kinase-1 Inhibitor PF-04965842 in Healthy Western and Japanese Subjects

NCT01835197
View directory record Official record
Conditions
Healthy
Interventions
PF-04965842, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 20, 2014 · Synced Oct 13, 2026, 9:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder (TPIP) in Healthy Participants

NCT06091579
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Treprostinil Palmitil Inhalation Powder, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 45 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2023 · Synced Oct 13, 2026, 9:05 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase 2 Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT

NCT03172910
View directory record Official record
Conditions
Healthy
Interventions
Ciraparantag, Placebo, Rivaroxaban
Drug
Lead sponsor
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 75 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Oct 13, 2026, 9:05 AM EDT
Completed Phase 3 Interventional Results available

Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer

NCT03349710
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Nivolumab, Cetuximab, Cisplatin, Radiotherapy
Biological · Drug · Radiation
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
21
States / cities
Anniston, Alabama • Goodyear, Arizona • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2021 · Synced Oct 13, 2026, 9:05 AM EDT
Completed Phase 2 Interventional Results available

Safety of Sildenafil in Premature Infants With Severe Bronchopulmonary Dysplasia

NCT04447989
View directory record Official record
Conditions
Bronchopulmonary Dysplasia of Newborn
Interventions
Sildenafil, Placebo
Drug
Lead sponsor
Christoph Hornik
Other
Eligibility
Up to 29 Weeks
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
25
States / cities
Little Rock, Arkansas • San Diego, California • Washington D.C., District of Columbia + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 13, 2026, 9:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of CR6261, a Monoclonal Antibody Against the Influenza A Virus

NCT01406418
View directory record Official record
Conditions
Influenza
Interventions
CR6261 2 mg/kg, CR6261 5 mg/kg, CR6261 15 mg/kg, CR6261 30 mg/kg, CR6261 50 mg/kg, Placebo
Biological
Lead sponsor
Crucell Holland BV
Industry
Eligibility
18 Years to 50 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Oct 13, 2026, 9:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7288 in Healthy Adult Volunteers

NCT01566877
View directory record Official record
Conditions
Marburg Hemorrhagic Fever
Interventions
AVI-7288, Placebo
Drug · Other
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Oct 13, 2026, 9:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety and Tolerability of Single Ascending Doses of REGN1033(SAR391786)

NCT01507402
View directory record Official record
Conditions
Healthy Volunteers
Interventions
REGN1033(SAR391786), Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
2
States / cities
Honolulu, Hawaii • Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 14, 2012 · Synced Oct 13, 2026, 9:05 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Repeat Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects

NCT02289495
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK2838232, Placebo, Ritonavir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 13, 2026, 9:05 AM EDT
Completed Phase 2 Interventional

Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus

NCT06152042
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
BMF-219
Drug
Lead sponsor
Biomea Fusion Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
9
States / cities
North Miami Beach, Florida • Morehead City, North Carolina • Norman, Oklahoma + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 13, 2026, 9:05 AM EDT
Withdrawn Phase 2 Interventional

Treatment of Chronic Itch in Atopic Dermatitis With Opioid Antagonist Naltrexone

NCT04325802
View directory record Official record
Conditions
Atopic Dermatitis, Pruritus, Pruritus Chronic, Dermatitis
Interventions
Naltrexone, Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Oct 13, 2026, 9:05 AM EDT
Completed Phase 2 Interventional Results available

A Dose-range Finding Study of MAA868 in Patients With Atrial Fibrillation

NCT04213807
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
MAA868 Cohort 1, MAA868 Cohort 2, MAA868 Cohort 3, Placebo
Biological · Other
Lead sponsor
Anthos Therapeutics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
6
States / cities
Beverly Hills, California • Wichita, Kansas • Alexandria, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 13, 2026, 9:05 AM EDT
Completed Phase 1Phase 2 Interventional

Evaluation of the Safety and Tolerability of Gemini in Subjects With Stage 3-4 Chronic Kidney Disease.

NCT06863467
View directory record Official record
Conditions
Renal Insufficiency, Chronic, Chronic Kidney Disease stage3, Chronic Kidney Disease stage4
Interventions
Intravenous Gemini, Intravenous placebo
Drug
Lead sponsor
Revelation Biosciences, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
3
States / cities
Chula Vista, California • La Mesa, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 13, 2026, 9:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug Interaction Study of LY3154207 in Healthy Participants

NCT03942029
View directory record Official record
Conditions
Healthy
Interventions
LY3154207 Capsule, LY3154207 Tablet, Placebo, Fluconazole Tablet
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 13, 2026, 9:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of Intravenous (IV) Infusion of MTP-131 (Bendavia™) in Healthy Adults

NCT01115920
View directory record Official record
Conditions
Healthy
Interventions
MTP-131 (Bendavia™)
Drug
Lead sponsor
Stealth BioTherapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 18, 2010 · Synced Oct 13, 2026, 9:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 in Healthy Subjects

NCT03906006
View directory record Official record
Conditions
Gout, Hyperuricemia
Interventions
ABP-671, Placebo
Drug · Other
Lead sponsor
Atom Therapeutics Co., Ltd
Industry
Eligibility
18 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 29, 2020 · Synced Oct 13, 2026, 9:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single-Dose Study of the Safety and Tolerability of REGN475(SAR164877) in Healthy Subjects

NCT00856310
View directory record Official record
Conditions
Healthy
Interventions
REGN475 (SAR164877)
Biological
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
21 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Altoona, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 10, 2012 · Synced Oct 13, 2026, 9:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Tolerability of PRO 140 in HIV Uninfected Male Volunteers

NCT00110591
View directory record Official record
Conditions
HIV Infections
Interventions
PRO 140
Drug
Lead sponsor
CytoDyn, Inc.
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Oct 13, 2026, 9:05 AM EDT
Completed Phase 1 Interventional

A Multiple-dose Study of the Safety and Tolerability of REGN88(SAR153191) in Rheumatoid Arthritis Subjects

NCT01011959
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
REGN88
Biological
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
24
States / cities
Santa Maria, California • Boca Raton, Florida • Clearwater, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Oct 13, 2026, 9:05 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients

NCT02190604
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Placebo, QBW251
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
9
States / cities
Birmingham, Alabama • Denver, Colorado • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2020 · Synced Oct 13, 2026, 9:05 AM EDT